In Brief: Biogen's Avonex
Executive Summary
Biogen's Avonex: Interferon beta-1a product for multiple sclerosis will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on Dec. 4. Biogen filed a PLA for Avonex in May based on Phase III data showing a 40% increase in time to disability and a 75% slowing in the rate of disease progression ("The Pink Sheet" Sept. 25, T&G-6). The meeting will begin at 8:30 a.m. in FDA's Parklawn building conference rooms D & E...
Biogen's Avonex: Interferon beta-1a product for multiple sclerosis will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on Dec. 4. Biogen filed a PLA for Avonex in May based on Phase III data showing a 40% increase in time to disability and a 75% slowing in the rate of disease progression ("The Pink Sheet" Sept. 25, T&G-6). The meeting will begin at 8:30 a.m. in FDA's Parklawn building conference rooms D & E.... |